In the BioHarmony Drug Report Database

"Preview" Icon

Daratumumab

Darzalex (daratumumab) is an antibody pharmaceutical. Daratumumab was first approved as Darzalex on 2015-11-16. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

 

Trade Name

 

Darzalex
 

Common Name

 

daratumumab
 

ChEMBL ID

 

CHEMBL1743007
 

Indication

 

multiple myeloma
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Daratumumab structure rendering